CEL-SCI Corporation (NYSE American: CVM) announced the closing of its best-efforts public offering, raising approximately $7.2 million in gross proceeds. The offering consisted of 6 million shares of common stock priced at $1.20 per share, before fees and expenses. The company stated that net proceeds will be used to support continued development of Multikine, its investigational immunotherapy for head and neck cancer, as well as for general corporate purposes and working capital.
Multikine (Leukocyte Interleukin, Injection) is designed to be administered to patients right after diagnosis and before surgery, with the aim of boosting the immune system while it is still relatively intact. CEL-SCI believes that this approach, before surgery, radiotherapy, and chemotherapy can damage the immune system, may provide the greatest possible impact on survival. The therapy has been dosed in over 740 patients and has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
The successful closing of this offering provides CEL-SCI with additional capital to advance its clinical development program. For investors, the offering underscores the company's commitment to progressing Multikine through the regulatory process. The funds will help support ongoing and planned studies, as well as operational expenses. CEL-SCI operates from facilities in Vienna, Virginia, and near Baltimore, Maryland. Additional details about the offering are available in the full press release at https://ibn.fm/T5Ng2.
The public offering comes at a critical time for CEL-SCI, as the company seeks to bring Multikine to market. Head and neck cancer remains a significant global health challenge, and new treatment options are needed. Multikine's unique mechanism of action, targeting the tumor before other treatments compromise the immune system, could offer a novel approach. The FDA's Orphan Drug designation highlights the potential of Multikine to address an unmet medical need.
Investors and industry observers will be watching CEL-SCI's progress closely, as the company uses this capital to advance its pipeline. The company's focus on neoadjuvant immunotherapy could position it as a pioneer in this space. For more information about CEL-SCI and its technology, visit https://cel-sci.com/.
